152 related articles for article (PubMed ID: 2964344)
1. Erythromycin 2 percent gel in the treatment of acne vulgaris.
Pochi PE; Bagatell FK; Ellis CN; Stoughton RB; Whitmore CG; Saatjian GD; Sefton J
Cutis; 1988 Feb; 41(2):132-6. PubMed ID: 2964344
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris.
Marazzi P; Boorman GC; Donald AE; Davies HD
J Dermatolog Treat; 2002 Sep; 13(3):111-7. PubMed ID: 12227873
[TBL] [Abstract][Full Text] [Related]
3. Comparison of topical erythromycin 1.5 percent solution versus topical clindamycin phosphate 1.0 percent solution in the treatment of acne vulgaris.
Thomas DR; Raimer S; Smith EB
Cutis; 1982 Jun; 29(6):624-5, 628-32. PubMed ID: 6213379
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of a new erythromycin solution for acne vulgaris.
Rivkin L; Rapaport M
Cutis; 1980 May; 25(5):552-5. PubMed ID: 6445816
[TBL] [Abstract][Full Text] [Related]
5. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled trial.
Kellett N; West F; Finlay AY
Br J Dermatol; 2006 Mar; 154(3):524-32. PubMed ID: 16445786
[TBL] [Abstract][Full Text] [Related]
6. A randomized, single-blind comparison of topical clindamycin + benzoyl peroxide (Duac) and erythromycin + zinc acetate (Zineryt) in the treatment of mild to moderate facial acne vulgaris.
Langner A; Sheehan-Dare R; Layton A
J Eur Acad Dermatol Venereol; 2007 Mar; 21(3):311-9. PubMed ID: 17309451
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne.
Richter JR; Förström LR; Kiistala UO; Jung EG
J Eur Acad Dermatol Venereol; 1998 Nov; 11(3):227-33. PubMed ID: 9883434
[TBL] [Abstract][Full Text] [Related]
8. Erythromycin 2% gel in comparison with clindamycin phosphate 1% solution in acne vulgaris.
Leyden JJ; Shalita AR; Saatjian GD; Sefton J
J Am Acad Dermatol; 1987 Apr; 16(4):822-7. PubMed ID: 2952685
[TBL] [Abstract][Full Text] [Related]
9. Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of mild to moderate acne.
Tunca M; Akar A; Ozmen I; Erbil H
Int J Dermatol; 2010 Dec; 49(12):1440-4. PubMed ID: 21091683
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Once-Daily Dapsone Gel, 7.5% for Treatment of Adolescents and Adults With Acne Vulgaris: Second of Two Identically Designed, Large, Multicenter, Randomized, Vehicle-Controlled Trials.
Eichenfield LF; Lain T; Frankel EH; Jones TM; Chang-Lin JE; Berk DR; Ruan S; Kaoukhov A
J Drugs Dermatol; 2016 Aug; 15(8):962-9. PubMed ID: 27537997
[TBL] [Abstract][Full Text] [Related]
11. Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial.
Ozolins M; Eady EA; Avery AJ; Cunliffe WJ; Po AL; O'Neill C; Simpson NB; Walters CE; Carnegie E; Lewis JB; Dada J; Haynes M; Williams K; Williams HC
Lancet; 2004 Dec 18-31; 364(9452):2188-95. PubMed ID: 15610805
[TBL] [Abstract][Full Text] [Related]
12. Clinical assessment of topical erythromycin gel with and without zinc acetate for treating mild-to-moderate acne vulgaris.
Sayyafan MS; Ramzi M; Salmanpour R
J Dermatolog Treat; 2020 Nov; 31(7):730-733. PubMed ID: 30998422
[No Abstract] [Full Text] [Related]
13. A topical azithromycin preparation for the treatment of acne vulgaris and rosacea.
McHugh RC; Rice A; Sangha ND; McCarty MA; Utterback R; Rohrback JM; Osborne BE; Fleischer AB; Feldman SR
J Dermatolog Treat; 2004 Sep; 15(5):295-302. PubMed ID: 15370397
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of topical erythromycin and oral tetracycline in acne vulgaris.
Rapaport M; Puhvel SM; Reisner RM
Cutis; 1982 Jul; 30(1):122-6, 130, 132-5. PubMed ID: 6214377
[TBL] [Abstract][Full Text] [Related]
15. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study.
Shalita AR; Chalker DK; Griffith RF; Herbert AA; Hickman JG; Maloney JM; Miller BH; Tschen EH; Chandraratna RA; Gibson JR; Lew-Kaya DA; Lue JC; Sefton J
Cutis; 1999 Jun; 63(6):349-54. PubMed ID: 10388959
[TBL] [Abstract][Full Text] [Related]
16. Topical erythromycin v clindamycin therapy for acne. A multicenter, double-blind comparison.
Shahlita AR; Smith EB; Bauer E
Arch Dermatol; 1984 Mar; 120(3):351-5. PubMed ID: 6230999
[TBL] [Abstract][Full Text] [Related]
17. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
Shalita AR; Berson DS; Thiboutot DM; Leyden JJ; Parizadeh D; Sefton J; Walker PS; Gibson JR;
Clin Ther; 2004 Nov; 26(11):1865-73. PubMed ID: 15639698
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy.
Draelos ZD; Tanghetti EA;
Cutis; 2002 Feb; 69(2 Suppl):20-9. PubMed ID: 12095065
[TBL] [Abstract][Full Text] [Related]
19. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1% gel and adapalene 0.1% gel for the treatment of facial acne vulgaris.
Webster GF; Guenther L; Poulin YP; Solomon BA; Loven K; Lee J
Cutis; 2002 Feb; 69(2 Suppl):4-11. PubMed ID: 12095066
[TBL] [Abstract][Full Text] [Related]
20. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial.
Leyden JJ; Tanghetti EA; Miller B; Ung M; Berson D; Lee J
Cutis; 2002 Feb; 69(2 Suppl):12-9. PubMed ID: 12095064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
